DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1604)

Malignant Melanoma | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (EU5)

Malignant Melanoma | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (EU5)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming June 2018

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.

Key Benefits:

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

Questions Answered:

  • Where is my product positioned vs. competitors’ in the treatment journey?
  • What are physicians’ most frequent treatment sequences—who is benefiting, and how can I defend my asset’s share and position?
  • What are the market-relevant treatment scenarios according to oncology experts?
  • How can I optimize trial design and ensure a competitive edge for my pipeline asset?
Coming soon
  • Pub Date: June 2018
  • Author(s): Swati Tyagi, M.Sc, MBA

Request report

Related reports:
You may also be interested in: